Novel Nanomicellar Formulation Approaches for Anterior and Posterior Segment Ocular Drug Delivery.
about
In Vitro Cell Models for Ophthalmic Drug Development ApplicationsTopical, Aqueous, Clear Cyclosporine Formulation Design for Anterior and Posterior Ocular Delivery.Topical delivery of aqueous micellar resolvin E1 analog (RX-10045)Novel strategies for anterior segment ocular drug delivery.Recent developments in protein and peptide parenteral delivery approaches.Ocular drug delivery systems: An overview.Nanocarrier mediated retinal drug delivery: overcoming ocular barriers to treat posterior eye diseases.Recent perspectives on the delivery of biologics to back of the eye.Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies.Nanomicelles: an emerging platform for drug delivery to the eye.Aqueous nanomicellar formulation for topical delivery of biotinylated lipid prodrug of acyclovir: formulation development and ocular biocompatibility.Optimization of dexamethasone mixed nanomicellar formulation.Modern Therapeutic Approaches for Noninfectious Ocular Diseases Involving Inflammation.How are we improving the delivery to back of the eye? Advances and challenges of novel therapeutic approaches.Topical ophthalmic lipid nanoparticle formulations (SLN, NLC) of indomethacin for delivery to the posterior segment ocular tissues.Functional intercalated nanocomposites with chitosan-glutathione-glycylsarcosine and layered double hydroxides for topical ocular drug delivery.Ocular Drug Delivery Barriers-Role of Nanocarriers in the Treatment of Anterior Segment Ocular Diseases.
P2860
Q26751148-9CE5AB61-D7CF-4D19-B8CA-53498FC36130Q35565484-132D3561-4895-4288-9260-B2A329858EB4Q37231179-6CCA98BD-633A-4D79-85D8-67447A542C89Q38065184-ABC86DB1-18B9-4F21-B301-65C95BAE2DF8Q38193174-D9CC8E6F-B879-43FA-9EA3-7925FFE27C4BQ38318837-20F90323-C5E0-47C8-AC90-FDD74F2861D3Q38829320-2C51DDDA-926C-4E27-83C3-2153510E544BQ38940171-9F8E2BE9-9B6E-4F5C-A903-BF8C5B6A6A7CQ39087808-B24CD113-0673-4DAD-AB6C-9FEF5AF9617CQ39867514-B089E5B0-E365-4532-8211-0B48AFDA9B3FQ40980060-B6BF727D-3733-4A58-8CBA-83A066A1E712Q41987702-528AE291-CE11-4825-96BC-D41D2587F0B5Q47442388-29306949-85A4-45D8-BFF9-70F7F5F30968Q48902538-382251DF-BAD5-4741-A990-70A3EC64A437Q50278439-87CF2286-BFE2-4168-9BE0-F46FF0BDBDA5Q50335529-C6DC6334-B620-4032-8142-A81AEC56D31AQ52679059-DB968973-8769-4E57-963B-AF57151E15B0
P2860
Novel Nanomicellar Formulation Approaches for Anterior and Posterior Segment Ocular Drug Delivery.
description
2012 nî lūn-bûn
@nan
2012 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2012 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
name
Novel Nanomicellar Formulation ...... Segment Ocular Drug Delivery.
@ast
Novel Nanomicellar Formulation ...... Segment Ocular Drug Delivery.
@en
Novel Nanomicellar Formulation ...... Segment Ocular Drug Delivery.
@nl
type
label
Novel Nanomicellar Formulation ...... Segment Ocular Drug Delivery.
@ast
Novel Nanomicellar Formulation ...... Segment Ocular Drug Delivery.
@en
Novel Nanomicellar Formulation ...... Segment Ocular Drug Delivery.
@nl
prefLabel
Novel Nanomicellar Formulation ...... Segment Ocular Drug Delivery.
@ast
Novel Nanomicellar Formulation ...... Segment Ocular Drug Delivery.
@en
Novel Nanomicellar Formulation ...... Segment Ocular Drug Delivery.
@nl
P2093
P2860
P1476
Novel Nanomicellar Formulation ...... Segment Ocular Drug Delivery.
@en
P2093
Ashaben Patel
Ashim K Mitra
Aswani Dutt Vadlapudi
Kishore Cholkar
P2860
P356
10.2174/1877912311202020082
P577
2012-01-01T00:00:00Z